top of page


A Phase 3,  Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotheraphy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)

Key Inclusion Criteria

  • Have not received any prior systemic anti-cancer therapy in metastatic setting. (Prior exposure to MET inhibitors, durvalumab, or sunitinib in any setting is not permitted.)

  • Centrally confirmed MET-driven PRCC without co-occurring FH mutations

  • Mandatory provision of FFPE tumour sample

  • Adequate organ and marrow functions

Key Exclusion Criteria

  • Symptomatic Spinal cord compression or brain metastases

  • Active HBV or HCV, eligible if resolved

  • Active or prior documented autoimmune or inflammatory disorders

  • Cardiac disease within last 6 months

  • Significant COVID-19 illness within 6 months

bottom of page